Product Information
SAPHRIS 2.5 MG TAB SUBLINGUAL is a brand product labeled by Allergan, Inc., priced at $20.9944 per EA under NDC 00456240260. Its NADAC has been published 455 times since Mar 23, 2016.
FDA first approved this application on Aug 13, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Allergan, Inc.NDC
00456240260
Classification
Brand
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
ASENAPINE MALEATEApproval Type
New Drug (NDA)
FDA Application
NDA022117FDA Approved
8/13/2009
TE Code
AB
On Market Since
12/30/2014
Pharmacological Classes
Price Statistics
The NADAC for SAPHRIS 2.5 MG TAB SUBLINGUAL has been published 455 times since Mar 23, 2016, and over the history we have for it it has risen 43.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.9944 per EA |
|---|---|
| All-time high | $21.0461 (Jun 10, 2026) |
| All-time low | $14.6009 (Mar 23, 2016) |
| 52-week high | $21.0461 |
| 52-week low | $20.0356 |
| Median price | $19.2130 |
| Average price | $18.9482 |
| Largest weekly change | +9.9% (Apr 13, 2016) |
| Weeks tracked | 455 |
| Tracking since | Mar 23, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Asenapine Maleate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Asenapine Maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAPHRIS 2.5 MG TAB SUBLINGUAL?
The current National Average Drug Acquisition Cost (NADAC) for SAPHRIS 2.5 MG TAB SUBLINGUAL, manufactured by Allergan, Inc., is $20.9944 per EA (NDC 00456240260), effective Sep 30, 2026.
How has the price of SAPHRIS 2.5 MG TAB SUBLINGUAL changed over time?
Over the history we have for it, the NADAC for SAPHRIS 2.5 MG TAB SUBLINGUAL has risen 43.8%. It has been tracked across 455 weekly CMS publications since Mar 23, 2016.
What are the highest and lowest recorded NADAC prices for SAPHRIS 2.5 MG TAB SUBLINGUAL?
Since Mar 23, 2016, the NADAC for SAPHRIS 2.5 MG TAB SUBLINGUAL has ranged from a low of $14.6009 (Mar 23, 2016) to a high of $21.0461 (Jun 10, 2026), with a median of $19.2130 per EA.
Are there cheaper alternatives to SAPHRIS 2.5 MG TAB SUBLINGUAL?
No other NADAC-published product currently shares the active ingredient and strength of SAPHRIS 2.5 MG TAB SUBLINGUAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SAPHRIS 2.5 MG TAB SUBLINGUAL?
SAPHRIS 2.5 MG TAB SUBLINGUAL (NDC 00456240260) is labeled by Allergan, Inc., and CMS classifies it as a brand product.